RapamycinFungusV1, Main, Exploration, bibRecord, 000319

Infectious complications after heart transplantation in patients screened with gene expression profiling.

Identifieur interne : 000319 ( Main/Exploration ); précédent : 000318; suivant : 000320

Infectious complications after heart transplantation in patients screened with gene expression profiling.

Auteurs : Yasbanoo Moayedi [Canada] ; Carlos A. Gomez [États-Unis] ; Chun Po S. Fan [Canada] ; Robert J H. Miller [États-Unis] ; Paul E. Bunce [Canada] ; Maxime Tremblay-Gravel [États-Unis] ; Farid Foroutan [Canada] ; Cedric Manlhiot [Canada] ; James Yee [États-Unis] ; Michael A. Shullo [États-Unis] ; Kiran K. Khush [États-Unis] ; Heather J. Ross [Canada] ; Jose G. Montoya [États-Unis] ; Jeffrey J. Teuteberg [États-Unis]

Source :

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation [ 1557-3117 ] ; 2019.

RBID : pubmed:30704838

Descripteurs français

KwdFr :
- Adulte (MeSH), Adulte d'âge moyen (MeSH), Analyse de profil d'expression de gènes (MeSH), Complications postopératoires (microbiologie), Complications postopératoires (épidémiologie), Défaillance cardiaque (chirurgie), Défaillance cardiaque (mortalité), Défaillance cardiaque (étiologie), Facteurs de risque (MeSH), Facteurs temps (MeSH), Femelle (MeSH), Glucocorticoïdes (usage thérapeutique), Hospitalisation (MeSH), Humains (MeSH), Immunosuppresseurs (usage thérapeutique), Infections à cytomégalovirus (épidémiologie), Mâle (MeSH), Prednisone (usage thérapeutique), Transplantation cardiaque (effets indésirables), Études de cohortes (MeSH).
MESH :
- chirurgie : Défaillance cardiaque.
- effets indésirables : Transplantation cardiaque.
- microbiologie : Complications postopératoires.
- mortalité : Défaillance cardiaque.
- usage thérapeutique : Glucocorticoïdes, Immunosuppresseurs, Prednisone.
- épidémiologie : Complications postopératoires, Infections à cytomégalovirus.
- étiologie : Défaillance cardiaque.
- Adulte, Adulte d'âge moyen, Analyse de profil d'expression de gènes, Facteurs de risque, Facteurs temps, Femelle, Hospitalisation, Humains, Mâle, Études de cohortes.

English descriptors

KwdEn :
- Adult (MeSH), Cohort Studies (MeSH), Cytomegalovirus Infections (epidemiology), Female (MeSH), Gene Expression Profiling (MeSH), Glucocorticoids (therapeutic use), Heart Failure (etiology), Heart Failure (mortality), Heart Failure (surgery), Heart Transplantation (adverse effects), Hospitalization (MeSH), Humans (MeSH), Immunosuppressive Agents (therapeutic use), Male (MeSH), Middle Aged (MeSH), Postoperative Complications (epidemiology), Postoperative Complications (microbiology), Prednisone (therapeutic use), Risk Factors (MeSH), Time Factors (MeSH).
MESH :
- chemical , therapeutic use : Glucocorticoids, Immunosuppressive Agents, Prednisone.
- adverse effects : Heart Transplantation.
- epidemiology : Cytomegalovirus Infections, Postoperative Complications.
- etiology : Heart Failure.
- microbiology : Postoperative Complications.
- mortality : Heart Failure.
- surgery : Heart Failure.
- Adult, Cohort Studies, Female, Gene Expression Profiling, Hospitalization, Humans, Male, Middle Aged, Risk Factors, Time Factors.

Abstract

BACKGROUND

The risk of infection after heart transplantation is highest within the first year and represents the leading cause of early mortality. In this cohort of patients enrolled in the Outcomes AlloMap Registry (OAR), we sought to describe infection episodes (IEp) resulting in hospitalization, in the early (<1 year) and late (≥1 year) post-transplant period and determine the impact of immunosuppression on incidence of infection.

METHODS

The primary aim was to assess the incidence and nature of IEp. The secondary aim was to evaluate the effect of potential risk factors, such as recipient age; sex; body mass index; panel-reactive antibodies; cytomegalovirus (CMV) primary mismatch; prednisone, tacrolimus, and sirolimus levels; and gene expression profile (GEP) score, in the development of IEp.

RESULTS

The OAR comprises 1,504 patients, of whom 220 patients (14.6%) had an IEp during a median follow-up period of 382 days (interquartile range [IQR] 230 to 579 days). The cause-specific 5-year hazard ratio for any infection was 2.029 (p = 0.12). The pattern of early infection was consistent with nosocomial and opportunistic causes, whereas later infection was consistent with late-onset opportunistic and community-acquired etiologies. Sixty-two percent of the infections occurred early. In the time-dependent analysis, higher prednisone dose (log prednisone, hazard ratio [HR] 1.30, p = 0.022) was the most significant risk factor for all IEp.

CONCLUSIONS

In the OAR cohort, the majority of infections occurred within 1 year after transplantation. Clinicians may consider more aggressive prednisone withdrawal in low-risk patients to reduce IEp.

DOI: 10.1016/j.healun.2019.01.006
PubMed: 30704838

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000355
to stream Main, to step Curation: 000355

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Infectious complications after heart transplantation in patients screened with gene expression profiling.</title>
<author><name sortKey="Moayedi, Yasbanoo" sort="Moayedi, Yasbanoo" uniqKey="Moayedi Y" first="Yasbanoo" last="Moayedi">Yasbanoo Moayedi</name>
<affiliation wicri:level="1"><nlm:affiliation>Section of Heart Failure, Cardiac Transplant, and Mechanical Circulatory Support, Department of Medicine, Stanford University, Stanford, California, USA; Ted Rogers Centre of Excellence for Heart Research, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Section of Heart Failure, Cardiac Transplant, and Mechanical Circulatory Support, Department of Medicine, Stanford University, Stanford, California, USA; Ted Rogers Centre of Excellence for Heart Research, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gomez, Carlos A" sort="Gomez, Carlos A" uniqKey="Gomez C" first="Carlos A" last="Gomez">Carlos A. Gomez</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Infectious Disease, Department of Medicine, Stanford University, Stanford, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Infectious Disease, Department of Medicine, Stanford University, Stanford, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fan, Chun Po S" sort="Fan, Chun Po S" uniqKey="Fan C" first="Chun Po S" last="Fan">Chun Po S. Fan</name>
<affiliation wicri:level="1"><nlm:affiliation>Ted Rogers Centre of Excellence for Heart Research, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Ted Rogers Centre of Excellence for Heart Research, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Miller, Robert J H" sort="Miller, Robert J H" uniqKey="Miller R" first="Robert J H" last="Miller">Robert J H. Miller</name>
<affiliation wicri:level="2"><nlm:affiliation>Section of Heart Failure, Cardiac Transplant, and Mechanical Circulatory Support, Department of Medicine, Stanford University, Stanford, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Section of Heart Failure, Cardiac Transplant, and Mechanical Circulatory Support, Department of Medicine, Stanford University, Stanford, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bunce, Paul E" sort="Bunce, Paul E" uniqKey="Bunce P" first="Paul E" last="Bunce">Paul E. Bunce</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Division of Infectious Disease, University Health Network, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, Division of Infectious Disease, University Health Network, University of Toronto, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tremblay Gravel, Maxime" sort="Tremblay Gravel, Maxime" uniqKey="Tremblay Gravel M" first="Maxime" last="Tremblay-Gravel">Maxime Tremblay-Gravel</name>
<affiliation wicri:level="2"><nlm:affiliation>Section of Heart Failure, Cardiac Transplant, and Mechanical Circulatory Support, Department of Medicine, Stanford University, Stanford, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Section of Heart Failure, Cardiac Transplant, and Mechanical Circulatory Support, Department of Medicine, Stanford University, Stanford, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Foroutan, Farid" sort="Foroutan, Farid" uniqKey="Foroutan F" first="Farid" last="Foroutan">Farid Foroutan</name>
<affiliation wicri:level="1"><nlm:affiliation>Ted Rogers Centre of Excellence for Heart Research, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Ted Rogers Centre of Excellence for Heart Research, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Manlhiot, Cedric" sort="Manlhiot, Cedric" uniqKey="Manlhiot C" first="Cedric" last="Manlhiot">Cedric Manlhiot</name>
<affiliation wicri:level="1"><nlm:affiliation>Ted Rogers Centre of Excellence for Heart Research, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Ted Rogers Centre of Excellence for Heart Research, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Yee, James" sort="Yee, James" uniqKey="Yee J" first="James" last="Yee">James Yee</name>
<affiliation wicri:level="2"><nlm:affiliation>CareDx, Inc., Brisbane, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>CareDx, Inc., Brisbane, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shullo, Michael A" sort="Shullo, Michael A" uniqKey="Shullo M" first="Michael A" last="Shullo">Michael A. Shullo</name>
<affiliation wicri:level="2"><nlm:affiliation>department of Medicine, West Virginia University, Morgantown, West Virginia, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>department of Medicine, West Virginia University, Morgantown, West Virginia</wicri:regionArea>
<placeName><region type="state">Virginie-Occidentale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Khush, Kiran K" sort="Khush, Kiran K" uniqKey="Khush K" first="Kiran K" last="Khush">Kiran K. Khush</name>
<affiliation wicri:level="2"><nlm:affiliation>Section of Heart Failure, Cardiac Transplant, and Mechanical Circulatory Support, Department of Medicine, Stanford University, Stanford, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Section of Heart Failure, Cardiac Transplant, and Mechanical Circulatory Support, Department of Medicine, Stanford University, Stanford, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ross, Heather J" sort="Ross, Heather J" uniqKey="Ross H" first="Heather J" last="Ross">Heather J. Ross</name>
<affiliation wicri:level="1"><nlm:affiliation>Ted Rogers Centre of Excellence for Heart Research, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Ted Rogers Centre of Excellence for Heart Research, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Montoya, Jose G" sort="Montoya, Jose G" uniqKey="Montoya J" first="Jose G" last="Montoya">Jose G. Montoya</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Infectious Disease, Department of Medicine, Stanford University, Stanford, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Infectious Disease, Department of Medicine, Stanford University, Stanford, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Teuteberg, Jeffrey J" sort="Teuteberg, Jeffrey J" uniqKey="Teuteberg J" first="Jeffrey J" last="Teuteberg">Jeffrey J. Teuteberg</name>
<affiliation wicri:level="2"><nlm:affiliation>Section of Heart Failure, Cardiac Transplant, and Mechanical Circulatory Support, Department of Medicine, Stanford University, Stanford, California, USA. Electronic address: jeff.teuteberg@stanford.edu.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Section of Heart Failure, Cardiac Transplant, and Mechanical Circulatory Support, Department of Medicine, Stanford University, Stanford, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2019">2019</date>
<idno type="RBID">pubmed:30704838</idno>
<idno type="pmid">30704838</idno>
<idno type="doi">10.1016/j.healun.2019.01.006</idno>
<idno type="wicri:Area/Main/Corpus">000355</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000355</idno>
<idno type="wicri:Area/Main/Curation">000355</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000355</idno>
<idno type="wicri:Area/Main/Exploration">000355</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Infectious complications after heart transplantation in patients screened with gene expression profiling.</title>
<author><name sortKey="Moayedi, Yasbanoo" sort="Moayedi, Yasbanoo" uniqKey="Moayedi Y" first="Yasbanoo" last="Moayedi">Yasbanoo Moayedi</name>
<affiliation wicri:level="1"><nlm:affiliation>Section of Heart Failure, Cardiac Transplant, and Mechanical Circulatory Support, Department of Medicine, Stanford University, Stanford, California, USA; Ted Rogers Centre of Excellence for Heart Research, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Section of Heart Failure, Cardiac Transplant, and Mechanical Circulatory Support, Department of Medicine, Stanford University, Stanford, California, USA; Ted Rogers Centre of Excellence for Heart Research, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Gomez, Carlos A" sort="Gomez, Carlos A" uniqKey="Gomez C" first="Carlos A" last="Gomez">Carlos A. Gomez</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Infectious Disease, Department of Medicine, Stanford University, Stanford, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Infectious Disease, Department of Medicine, Stanford University, Stanford, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Fan, Chun Po S" sort="Fan, Chun Po S" uniqKey="Fan C" first="Chun Po S" last="Fan">Chun Po S. Fan</name>
<affiliation wicri:level="1"><nlm:affiliation>Ted Rogers Centre of Excellence for Heart Research, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Ted Rogers Centre of Excellence for Heart Research, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Miller, Robert J H" sort="Miller, Robert J H" uniqKey="Miller R" first="Robert J H" last="Miller">Robert J H. Miller</name>
<affiliation wicri:level="2"><nlm:affiliation>Section of Heart Failure, Cardiac Transplant, and Mechanical Circulatory Support, Department of Medicine, Stanford University, Stanford, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Section of Heart Failure, Cardiac Transplant, and Mechanical Circulatory Support, Department of Medicine, Stanford University, Stanford, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bunce, Paul E" sort="Bunce, Paul E" uniqKey="Bunce P" first="Paul E" last="Bunce">Paul E. Bunce</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, Division of Infectious Disease, University Health Network, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine, Division of Infectious Disease, University Health Network, University of Toronto, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tremblay Gravel, Maxime" sort="Tremblay Gravel, Maxime" uniqKey="Tremblay Gravel M" first="Maxime" last="Tremblay-Gravel">Maxime Tremblay-Gravel</name>
<affiliation wicri:level="2"><nlm:affiliation>Section of Heart Failure, Cardiac Transplant, and Mechanical Circulatory Support, Department of Medicine, Stanford University, Stanford, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Section of Heart Failure, Cardiac Transplant, and Mechanical Circulatory Support, Department of Medicine, Stanford University, Stanford, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Foroutan, Farid" sort="Foroutan, Farid" uniqKey="Foroutan F" first="Farid" last="Foroutan">Farid Foroutan</name>
<affiliation wicri:level="1"><nlm:affiliation>Ted Rogers Centre of Excellence for Heart Research, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Ted Rogers Centre of Excellence for Heart Research, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Manlhiot, Cedric" sort="Manlhiot, Cedric" uniqKey="Manlhiot C" first="Cedric" last="Manlhiot">Cedric Manlhiot</name>
<affiliation wicri:level="1"><nlm:affiliation>Ted Rogers Centre of Excellence for Heart Research, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Ted Rogers Centre of Excellence for Heart Research, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Yee, James" sort="Yee, James" uniqKey="Yee J" first="James" last="Yee">James Yee</name>
<affiliation wicri:level="2"><nlm:affiliation>CareDx, Inc., Brisbane, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>CareDx, Inc., Brisbane, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shullo, Michael A" sort="Shullo, Michael A" uniqKey="Shullo M" first="Michael A" last="Shullo">Michael A. Shullo</name>
<affiliation wicri:level="2"><nlm:affiliation>department of Medicine, West Virginia University, Morgantown, West Virginia, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>department of Medicine, West Virginia University, Morgantown, West Virginia</wicri:regionArea>
<placeName><region type="state">Virginie-Occidentale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Khush, Kiran K" sort="Khush, Kiran K" uniqKey="Khush K" first="Kiran K" last="Khush">Kiran K. Khush</name>
<affiliation wicri:level="2"><nlm:affiliation>Section of Heart Failure, Cardiac Transplant, and Mechanical Circulatory Support, Department of Medicine, Stanford University, Stanford, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Section of Heart Failure, Cardiac Transplant, and Mechanical Circulatory Support, Department of Medicine, Stanford University, Stanford, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Ross, Heather J" sort="Ross, Heather J" uniqKey="Ross H" first="Heather J" last="Ross">Heather J. Ross</name>
<affiliation wicri:level="1"><nlm:affiliation>Ted Rogers Centre of Excellence for Heart Research, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Ted Rogers Centre of Excellence for Heart Research, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Montoya, Jose G" sort="Montoya, Jose G" uniqKey="Montoya J" first="Jose G" last="Montoya">Jose G. Montoya</name>
<affiliation wicri:level="2"><nlm:affiliation>Division of Infectious Disease, Department of Medicine, Stanford University, Stanford, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Infectious Disease, Department of Medicine, Stanford University, Stanford, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Teuteberg, Jeffrey J" sort="Teuteberg, Jeffrey J" uniqKey="Teuteberg J" first="Jeffrey J" last="Teuteberg">Jeffrey J. Teuteberg</name>
<affiliation wicri:level="2"><nlm:affiliation>Section of Heart Failure, Cardiac Transplant, and Mechanical Circulatory Support, Department of Medicine, Stanford University, Stanford, California, USA. Electronic address: jeff.teuteberg@stanford.edu.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Section of Heart Failure, Cardiac Transplant, and Mechanical Circulatory Support, Department of Medicine, Stanford University, Stanford, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</title>
<idno type="eISSN">1557-3117</idno>
<imprint><date when="2019" type="published">2019</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term>
<term>Cohort Studies (MeSH)</term>
<term>Cytomegalovirus Infections (epidemiology)</term>
<term>Female (MeSH)</term>
<term>Gene Expression Profiling (MeSH)</term>
<term>Glucocorticoids (therapeutic use)</term>
<term>Heart Failure (etiology)</term>
<term>Heart Failure (mortality)</term>
<term>Heart Failure (surgery)</term>
<term>Heart Transplantation (adverse effects)</term>
<term>Hospitalization (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Immunosuppressive Agents (therapeutic use)</term>
<term>Male (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Postoperative Complications (epidemiology)</term>
<term>Postoperative Complications (microbiology)</term>
<term>Prednisone (therapeutic use)</term>
<term>Risk Factors (MeSH)</term>
<term>Time Factors (MeSH)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term>
<term>Adulte d'âge moyen (MeSH)</term>
<term>Analyse de profil d'expression de gènes (MeSH)</term>
<term>Complications postopératoires (microbiologie)</term>
<term>Complications postopératoires (épidémiologie)</term>
<term>Défaillance cardiaque (chirurgie)</term>
<term>Défaillance cardiaque (mortalité)</term>
<term>Défaillance cardiaque (étiologie)</term>
<term>Facteurs de risque (MeSH)</term>
<term>Facteurs temps (MeSH)</term>
<term>Femelle (MeSH)</term>
<term>Glucocorticoïdes (usage thérapeutique)</term>
<term>Hospitalisation (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Immunosuppresseurs (usage thérapeutique)</term>
<term>Infections à cytomégalovirus (épidémiologie)</term>
<term>Mâle (MeSH)</term>
<term>Prednisone (usage thérapeutique)</term>
<term>Transplantation cardiaque (effets indésirables)</term>
<term>Études de cohortes (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Glucocorticoids</term>
<term>Immunosuppressive Agents</term>
<term>Prednisone</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Heart Transplantation</term>
</keywords>
<keywords scheme="MESH" qualifier="chirurgie" xml:lang="fr"><term>Défaillance cardiaque</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Transplantation cardiaque</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Cytomegalovirus Infections</term>
<term>Postoperative Complications</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Heart Failure</term>
</keywords>
<keywords scheme="MESH" qualifier="microbiologie" xml:lang="fr"><term>Complications postopératoires</term>
</keywords>
<keywords scheme="MESH" qualifier="microbiology" xml:lang="en"><term>Postoperative Complications</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Heart Failure</term>
</keywords>
<keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Défaillance cardiaque</term>
</keywords>
<keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Heart Failure</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Glucocorticoïdes</term>
<term>Immunosuppresseurs</term>
<term>Prednisone</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Complications postopératoires</term>
<term>Infections à cytomégalovirus</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Défaillance cardiaque</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Cohort Studies</term>
<term>Female</term>
<term>Gene Expression Profiling</term>
<term>Hospitalization</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Risk Factors</term>
<term>Time Factors</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Analyse de profil d'expression de gènes</term>
<term>Facteurs de risque</term>
<term>Facteurs temps</term>
<term>Femelle</term>
<term>Hospitalisation</term>
<term>Humains</term>
<term>Mâle</term>
<term>Études de cohortes</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b>
</p>
<p>The risk of infection after heart transplantation is highest within the first year and represents the leading cause of early mortality. In this cohort of patients enrolled in the Outcomes AlloMap Registry (OAR), we sought to describe infection episodes (IEp) resulting in hospitalization, in the early (<1 year) and late (≥1 year) post-transplant period and determine the impact of immunosuppression on incidence of infection.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>METHODS</b>
</p>
<p>The primary aim was to assess the incidence and nature of IEp. The secondary aim was to evaluate the effect of potential risk factors, such as recipient age; sex; body mass index; panel-reactive antibodies; cytomegalovirus (CMV) primary mismatch; prednisone, tacrolimus, and sirolimus levels; and gene expression profile (GEP) score, in the development of IEp.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>The OAR comprises 1,504 patients, of whom 220 patients (14.6%) had an IEp during a median follow-up period of 382 days (interquartile range [IQR] 230 to 579 days). The cause-specific 5-year hazard ratio for any infection was 2.029 (p = 0.12). The pattern of early infection was consistent with nosocomial and opportunistic causes, whereas later infection was consistent with late-onset opportunistic and community-acquired etiologies. Sixty-two percent of the infections occurred early. In the time-dependent analysis, higher prednisone dose (log prednisone, hazard ratio [HR] 1.30, p = 0.022) was the most significant risk factor for all IEp.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b>
</p>
<p>In the OAR cohort, the majority of infections occurred within 1 year after transplantation. Clinicians may consider more aggressive prednisone withdrawal in low-risk patients to reduce IEp.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30704838</PMID>
<DateCompleted><Year>2020</Year>
<Month>11</Month>
<Day>10</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>11</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1557-3117</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>38</Volume>
<Issue>6</Issue>
<PubDate><Year>2019</Year>
<Month>06</Month>
</PubDate>
</JournalIssue>
<Title>The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</Title>
<ISOAbbreviation>J Heart Lung Transplant</ISOAbbreviation>
</Journal>
<ArticleTitle>Infectious complications after heart transplantation in patients screened with gene expression profiling.</ArticleTitle>
<Pagination><MedlinePgn>611-618</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S1053-2498(19)30006-3</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.healun.2019.01.006</ELocationID>
<Abstract><AbstractText Label="BACKGROUND">The risk of infection after heart transplantation is highest within the first year and represents the leading cause of early mortality. In this cohort of patients enrolled in the Outcomes AlloMap Registry (OAR), we sought to describe infection episodes (IEp) resulting in hospitalization, in the early (<1 year) and late (≥1 year) post-transplant period and determine the impact of immunosuppression on incidence of infection.</AbstractText>
<AbstractText Label="METHODS">The primary aim was to assess the incidence and nature of IEp. The secondary aim was to evaluate the effect of potential risk factors, such as recipient age; sex; body mass index; panel-reactive antibodies; cytomegalovirus (CMV) primary mismatch; prednisone, tacrolimus, and sirolimus levels; and gene expression profile (GEP) score, in the development of IEp.</AbstractText>
<AbstractText Label="RESULTS">The OAR comprises 1,504 patients, of whom 220 patients (14.6%) had an IEp during a median follow-up period of 382 days (interquartile range [IQR] 230 to 579 days). The cause-specific 5-year hazard ratio for any infection was 2.029 (p = 0.12). The pattern of early infection was consistent with nosocomial and opportunistic causes, whereas later infection was consistent with late-onset opportunistic and community-acquired etiologies. Sixty-two percent of the infections occurred early. In the time-dependent analysis, higher prednisone dose (log prednisone, hazard ratio [HR] 1.30, p = 0.022) was the most significant risk factor for all IEp.</AbstractText>
<AbstractText Label="CONCLUSIONS">In the OAR cohort, the majority of infections occurred within 1 year after transplantation. Clinicians may consider more aggressive prednisone withdrawal in low-risk patients to reduce IEp.</AbstractText>
<CopyrightInformation>Copyright © 2019 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moayedi</LastName>
<ForeName>Yasbanoo</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Section of Heart Failure, Cardiac Transplant, and Mechanical Circulatory Support, Department of Medicine, Stanford University, Stanford, California, USA; Ted Rogers Centre of Excellence for Heart Research, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gomez</LastName>
<ForeName>Carlos A</ForeName>
<Initials>CA</Initials>
<AffiliationInfo><Affiliation>Division of Infectious Disease, Department of Medicine, Stanford University, Stanford, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Fan</LastName>
<ForeName>Chun Po S</ForeName>
<Initials>CPS</Initials>
<AffiliationInfo><Affiliation>Ted Rogers Centre of Excellence for Heart Research, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Miller</LastName>
<ForeName>Robert J H</ForeName>
<Initials>RJH</Initials>
<AffiliationInfo><Affiliation>Section of Heart Failure, Cardiac Transplant, and Mechanical Circulatory Support, Department of Medicine, Stanford University, Stanford, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bunce</LastName>
<ForeName>Paul E</ForeName>
<Initials>PE</Initials>
<AffiliationInfo><Affiliation>Department of Medicine, Division of Infectious Disease, University Health Network, University of Toronto, Toronto, Ontario, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Tremblay-Gravel</LastName>
<ForeName>Maxime</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Section of Heart Failure, Cardiac Transplant, and Mechanical Circulatory Support, Department of Medicine, Stanford University, Stanford, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Foroutan</LastName>
<ForeName>Farid</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Ted Rogers Centre of Excellence for Heart Research, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Manlhiot</LastName>
<ForeName>Cedric</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Ted Rogers Centre of Excellence for Heart Research, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Yee</LastName>
<ForeName>James</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>CareDx, Inc., Brisbane, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Shullo</LastName>
<ForeName>Michael A</ForeName>
<Initials>MA</Initials>
<AffiliationInfo><Affiliation>department of Medicine, West Virginia University, Morgantown, West Virginia, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Khush</LastName>
<ForeName>Kiran K</ForeName>
<Initials>KK</Initials>
<AffiliationInfo><Affiliation>Section of Heart Failure, Cardiac Transplant, and Mechanical Circulatory Support, Department of Medicine, Stanford University, Stanford, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ross</LastName>
<ForeName>Heather J</ForeName>
<Initials>HJ</Initials>
<AffiliationInfo><Affiliation>Ted Rogers Centre of Excellence for Heart Research, Peter Munk Cardiac Centre, University Health Network, Toronto, Ontario, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Montoya</LastName>
<ForeName>Jose G</ForeName>
<Initials>JG</Initials>
<AffiliationInfo><Affiliation>Division of Infectious Disease, Department of Medicine, Stanford University, Stanford, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Teuteberg</LastName>
<ForeName>Jeffrey J</ForeName>
<Initials>JJ</Initials>
<AffiliationInfo><Affiliation>Section of Heart Failure, Cardiac Transplant, and Mechanical Circulatory Support, Department of Medicine, Stanford University, Stanford, California, USA. Electronic address: jeff.teuteberg@stanford.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2019</Year>
<Month>01</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Heart Lung Transplant</MedlineTA>
<NlmUniqueID>9102703</NlmUniqueID>
<ISSNLinking>1053-2498</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>VB0R961HZT</RegistryNumber>
<NameOfSubstance UI="D011241">Prednisone</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003586" MajorTopicYN="N">Cytomegalovirus Infections</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
<QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016027" MajorTopicYN="N">Heart Transplantation</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011241" MajorTopicYN="N">Prednisone</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">AlloMap</Keyword>
<Keyword MajorTopicYN="Y">cytomegalovirus</Keyword>
<Keyword MajorTopicYN="Y">heart transplantation</Keyword>
<Keyword MajorTopicYN="Y">immunosuppression</Keyword>
<Keyword MajorTopicYN="Y">infectious episode</Keyword>
<Keyword MajorTopicYN="Y">survival</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year>
<Month>04</Month>
<Day>17</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2018</Year>
<Month>12</Month>
<Day>19</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2019</Year>
<Month>01</Month>
<Day>03</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2019</Year>
<Month>2</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>11</Month>
<Day>11</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2019</Year>
<Month>2</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">30704838</ArticleId>
<ArticleId IdType="pii">S1053-2498(19)30006-3</ArticleId>
<ArticleId IdType="doi">10.1016/j.healun.2019.01.006</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Canada</li>
<li>États-Unis</li>
</country>
<region><li>Californie</li>
<li>Virginie-Occidentale</li>
</region>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Moayedi, Yasbanoo" sort="Moayedi, Yasbanoo" uniqKey="Moayedi Y" first="Yasbanoo" last="Moayedi">Yasbanoo Moayedi</name>
</noRegion>
<name sortKey="Bunce, Paul E" sort="Bunce, Paul E" uniqKey="Bunce P" first="Paul E" last="Bunce">Paul E. Bunce</name>
<name sortKey="Fan, Chun Po S" sort="Fan, Chun Po S" uniqKey="Fan C" first="Chun Po S" last="Fan">Chun Po S. Fan</name>
<name sortKey="Foroutan, Farid" sort="Foroutan, Farid" uniqKey="Foroutan F" first="Farid" last="Foroutan">Farid Foroutan</name>
<name sortKey="Manlhiot, Cedric" sort="Manlhiot, Cedric" uniqKey="Manlhiot C" first="Cedric" last="Manlhiot">Cedric Manlhiot</name>
<name sortKey="Ross, Heather J" sort="Ross, Heather J" uniqKey="Ross H" first="Heather J" last="Ross">Heather J. Ross</name>
</country>
<country name="États-Unis"><region name="Californie"><name sortKey="Gomez, Carlos A" sort="Gomez, Carlos A" uniqKey="Gomez C" first="Carlos A" last="Gomez">Carlos A. Gomez</name>
</region>
<name sortKey="Khush, Kiran K" sort="Khush, Kiran K" uniqKey="Khush K" first="Kiran K" last="Khush">Kiran K. Khush</name>
<name sortKey="Miller, Robert J H" sort="Miller, Robert J H" uniqKey="Miller R" first="Robert J H" last="Miller">Robert J H. Miller</name>
<name sortKey="Montoya, Jose G" sort="Montoya, Jose G" uniqKey="Montoya J" first="Jose G" last="Montoya">Jose G. Montoya</name>
<name sortKey="Shullo, Michael A" sort="Shullo, Michael A" uniqKey="Shullo M" first="Michael A" last="Shullo">Michael A. Shullo</name>
<name sortKey="Teuteberg, Jeffrey J" sort="Teuteberg, Jeffrey J" uniqKey="Teuteberg J" first="Jeffrey J" last="Teuteberg">Jeffrey J. Teuteberg</name>
<name sortKey="Tremblay Gravel, Maxime" sort="Tremblay Gravel, Maxime" uniqKey="Tremblay Gravel M" first="Maxime" last="Tremblay-Gravel">Maxime Tremblay-Gravel</name>
<name sortKey="Yee, James" sort="Yee, James" uniqKey="Yee J" first="James" last="Yee">James Yee</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Bois/explor/RapamycinFungusV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000319 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000319 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Bois
   |area=    RapamycinFungusV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:30704838
   |texte=   Infectious complications after heart transplantation in patients screened with gene expression profiling.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:30704838" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a RapamycinFungusV1

This area was generated with Dilib version V0.6.38.
Data generation: Thu Nov 19 21:55:41 2020. Site generation: Thu Nov 19 22:00:39 2020

	Serveur d'exploration sur la rapamycine et les champignons
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur la rapamycine et les champignons

Infectious complications after heart transplantation in patients screened with gene expression profiling.

Infectious complications after heart transplantation in patients screened with gene expression profiling.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki